問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

5307Cases

2024-07-01 - 2028-06-30

Others

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
1Sites

Recruiting1Sites

2026-03-01 - 2030-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes

  • Condition/Disease

    Obesity or Overweight 、Type 2 Diabetes Mellitus

  • Test Drug

    注射劑

Participate Sites
8Sites

Not yet recruiting1Sites

2024-07-01 - 2035-04-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2026-03-01 - 2030-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes

  • Condition/Disease

    Obesity or Overweight

  • Test Drug

    注射劑

Participate Sites
8Sites

Not yet recruiting1Sites

2024-07-01 - 2026-12-31

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2024-07-15 - 2026-08-31

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2024-07-08 - 2037-08-12

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
1Sites

Terminated1Sites

2026-05-01 - 2030-05-31

Phase III

Not yet recruiting
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma

  • Condition/Disease

    Advanced Clear Cell Renal Cell Carcinoma

  • Test Drug

    AB521 (Casdatifan) 25mg/ Placebo 30 tablets/bottle

Participate Sites
4Sites

Not yet recruiting1Sites

2024-07-17 - 2027-07-30

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
1Sites

Recruiting1Sites

2024-07-30 - 2028-09-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting8Sites

Recruiting4Sites

1 13 14 15 16 17 531
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB